Mirae Asset Global ETFs Holdings
FATE icon

Mirae Asset Global ETFs Holdings’s Fate Therapeutics FATE Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,619
Closed -$64.3K – 3220
2026
Q1 		$64.3K Buy
53,619
+1,246
+2% +$1.52K ﹤0.01% 2845
2025
Q4 		$51.5K Buy
52,373
+1,701
+3% +$2.04K ﹤0.01% 2927
2025
Q3 		$63.8K Sell
50,672
-6,649
-12% -$7.17K ﹤0.01% 2865
2025
Q2 		$64.2K Sell
57,321
-2,540
-4% -$2.95K ﹤0.01% 2814
2025
Q1 		$47.3K Buy
59,861
+2,580
+5% +$3.16K ﹤0.01% 2861
2024
Q4 		$94.5K Sell
57,281
-5,983
-9% -$15.1K ﹤0.01% 2725
2024
Q3 		$222K Buy
63,264
+11,520
+22% +$44.8K ﹤0.01% 2329
2024
Q2 		$170K Buy
+51,744
New +$227K ﹤0.01% 2338

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's FATE Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 53,619 shares — an estimated $64.3K sold.

Mirae Asset Global ETFs Holdings first reported a position in FATE in Q2 2024 and held it in 8 quarters. The position peaked at $222K in Q3 2024. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Mirae Asset Global ETFs Holdings reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 53,619 Fate Therapeutics shares in Q2 2026, an estimated $64.3K.
  • Mirae Asset Global ETFs Holdings first reported a position in Fate Therapeutics in Q2 2024 and held it in 8 quarters.
  • Mirae Asset Global ETFs Holdings's Fate Therapeutics position peaked at $222K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.